NCT06211166 Assessment of Measurable Residual Disease in Allo-HSCT Using Digital Polymerase Chain Reaction
| NCT ID | NCT06211166 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking University People's Hospital |
| Condition | Acute Leukemia |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2024-01-08 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2024-01-08 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A research investigation into the efficacy of digital Polymerase Chain Reaction (dPCR) for monitoring measurable residual disease (MRD) during allogeneic hematopoietic stem cell transplantation, with a focus on predicting relapse in patients diagnosed with leukemia, myelodysplastic syndromes (MDS), and related hematological conditions.
Eligibility Criteria
Inclusion Criteria: * The presence of at least one fusion gene or hematological tumor-associated mutation detected at diagnosis by NGS or real-time PCR provided for posttransplant MRD monitoring. * Neutrophil engraftment * Received at least one MRD monitoring by digital PCR after HSCT Exclusion Criteria: * Patients who relapsed or died before the first digital PCR monitoring * Patients only with mutations in DNMT3A, TET2, and ASXL1 ("DTA mutations") or only germline mutations
Contact & Investigator
Xiao-jun Huang, M.D
PRINCIPAL INVESTIGATOR
Peking University People's Hospital
Frequently Asked Questions
Who can join the NCT06211166 clinical trial?
This trial is open to participants of all sexes, studying Acute Leukemia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06211166 currently recruiting?
Yes, NCT06211166 is actively recruiting participants. Contact the research team at drlvmeng@163.com for enrollment information.
Where is the NCT06211166 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06211166 clinical trial?
NCT06211166 is sponsored by Peking University People's Hospital. The principal investigator is Xiao-jun Huang, M.D at Peking University People's Hospital. The trial plans to enroll 300 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.